期刊文献+

单用他达拉非及联用硫辛酸治疗2型糖尿病性ED的比较 被引量:7

Comparison of Tadalafil monotherapy and lipoic acid add-on therapy for type 2 diabetic ED
原文传递
导出
摘要 目的探讨单用他达拉非5mg/日以及联用硫辛酸治疗糖尿病性ED的临床疗效。方法选择2017年1月至2018年12月就诊我科的糖尿病性ED患者181例,经第一阶段他达拉非5mg/日治疗12周后,仍诉勃起功能障碍及部分合并射精功能障碍的43例患者纳入最终研究统计并接受第二阶段治疗;第二阶段采用他达拉非5mg/日联合硫辛酸治疗12周。最终纳入研究统计患者在治疗前及第一、第二阶段治疗后均使用IIEF-5、Rigiscan及男性射精功能评分量表分别评估勃起满意度、勃起功能、射精功能等并记录。通过三次结果分析单用他达拉非5mg/日及联用硫辛酸治疗糖尿病性勃起功能障碍及合并射精功能障碍的疗效。结果他达拉非5mg/日联合硫辛酸治疗较单用他达拉非5mg/日及治疗前均显著提高患者IIEF-5分值,差异有统计学意义(P<0.05);单用他达拉非5mg/日及联合硫辛酸治疗较治疗前Rigiscan检测参数均有提高,差异有统计学意义(P<0.05),他达拉非5mg/日联合硫辛酸相比单用他达拉非5mg/日除阴茎头部胀大活力单位(Tumescence Activity Units TAU)差异无统计学意义(P>0.05),其余参数差异均有统计学意义(P<0.05)。糖尿病性ED伴Ej D患者单用他达拉非5mg/日治疗后男性射精功能评分较治疗前差异无统计学意义(P>0.05);联用硫辛酸治疗后部分射精功能评分项改善,较治疗前及单用他达拉非5mg/日治疗差异有统计学意义(P<0.05)。结论单用他达拉非5mg/日或联用硫辛酸均可改善糖尿病性ED患者的勃起功能,联用硫辛酸可改善部分射精功能。 Objective To investigate the clinical efficacy of 5 mg Once a day(OAD)of tadalafil monotherapy and lipoic acid add-on therapy in the treatment of diabetic erectile dysfunction with or without ejaculatory dysfunction.Methods Total of 181 patients with diabetic erectile dysfunction who visited our department from January 2017 to December 2018 were recruited in the study.In the first stage,tadalafil 5 mg OAD monotherapy was used for 12 weeks.After the treatment,the patients who still complained of poor erectile function and combined with ejaculatory dysfunction were included in the final study statistics and received the second stage of treatment.In the second stage,tadalafil 5 mg OAD combined with lipoic acid were used for 12 weeks.All the final enrolled patients would receive the IIEF-5,Rigiscan and male ejaculation scoring scales to evaluate their erectile satisfaction,erectile function and ejaculatory function before treatment and after the two stages of treatment,and the corresponding records were recorded.The efficacy of tadalafil 5 mg OAD alone and lipoic acid add-on therapy in the treatment of diabetic erectile dysfunction and ejaculatory dysfunction were analyzed through the records.Results The patients who received the treatment of tadalafil 5 mg OAD combined with lipoic acid got a higher IIEF-5 score than those received treatment of tadalafil 5 mg OAD,and the difference was statistically significant(P<0.05).Compared with the Rigiscan detection parameters before treatment,both the treatment with tadalafil 5 mg OAD and lipoic acid add-on treatment increased,and the difference was statistically significant(P<0.05).Compared with all the Rigiscan parameters after the treatment of tadalafil 5 mg OAD combined with lipoic acid and tadalafil 5 mg OAD,there were statistically significant differences(p<0.05)except the tip TAU(P>0.05).There were no statistically significant differences in the male ejaculation scores between using the treatment of tadalafil 5 mg OAD and before treatment in the enrolled patients suffering from diabetic erectile and ejaculatory dysfunction(P>0.05).After the addition of lipoic acid,some patients’male ejaculatory scores got higher than the base and treatment with tadalafil 5 mg OAD,and the difference was statistically significant(P<0.05).Conclusions Both Tadalafil 5 mg OAD monotherapy and with lipoic acid add-on therapy can improve erectile function in patients with diabetic erectile dysfunction,tadalafil 5 mg OAD combined with lipoic acid therapy can partially improve ejaculatory function.
作者 唐松喜 陈书申 周辉良 易如海 丁一郎 杨鹏 陈强 黄海林 Tang Songxi;Chen Shushen;Zhou Huiliang;Yi Ruhai;Ding YiLan;Yang Peng;Chen Qiang;Huang Hailin(Department of Andrology,First affiliated Hospital of Fujian Medical University,Fuzhou,350005,China;Department of Endocrinology,First affiliated Hospital of Fujian Medical University,Fuzhou 350005,China)
出处 《中国男科学杂志》 CAS CSCD 2020年第1期31-35,共5页 Chinese Journal of Andrology
关键词 男性勃起功能障碍 糖尿病 2型 射精功能障碍 他达拉非 硫辛酸 Erectile dysfunction Diabetes mellitus type 2 Ejaculatory dysfunction Tadalafil Lipoic acid
  • 相关文献

参考文献4

二级参考文献32

  • 1李三祥,戴玉田.阴茎血管活性物质及其功能递质在勃起功能障碍发病中的作用[J].中华男科学杂志,2005,11(11):843-846. 被引量:9
  • 2Billups KL, Bank AJ, Padma-Nathan H, et al. Erectile dysfunction is a marker for cardiovascular disease: results of the minority health institute expert advisory panel. J Sex Med, 2005, 2( 1 ) : 40-50.
  • 3Najmutdinova D, Sadikova N. Use of alpha-lipoie acid in patients with type 1 diabetes mellitus. Diabetologia, 2007, 50( Suppl 1 ) : S514-S515.
  • 4Cheng M, Gao HQ, Xu L, et al. Cardioprotective effects of grape seed proanthocyanidins extracts in streptozocin induced diabetic rats. J Cardiovasc Pharmacol, 2007, 50 (5) : 503-509.
  • 5Stief CG. Central mechanisms of erectile dysfunction: what a clinician may want to know. Int J Impot Res, 2003, 15 (Suppl 2) : S3- S6.
  • 6Foxton MR, Quaglia A, Muiesan P, et al. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am J Transplant, 2006, 6(8) : 1922-1929.
  • 7Kalter-Leibovici O, Lifshitz A, Yerushalmy Y, et al. Comprehensive assessment of clinical, socioeconomic (SE) and lifestyle parameters associated with erectile dysfunction (ED) among diabetic men. Diabetologia, 2004, 47 (5) : A370-A370.
  • 8Reddy PN, Reddy PS, Rao MR. Studies on the effect of doxorubicin on MDA, NO2, NO3, Se-GSH peroxidase and SOD levels in albino rat tissues. Afr J Biotechnol, 2007, 6 (20) : 2303- 2309.
  • 9Zheng H, Bidasee KR, Mayhan WG, et al. Lack of central nitric oxide triggers erectile dysfunction in diabetes. Am J Physiol Regul Integr Comp Physiol, 2007, 292(3) : R1158-R1164.
  • 10Li H, Xu L, Dunbar JC, et al. Effects of C-peptide on expression of eNOS and iNOS in human cavernosal smooth muscle cells. Urology, 2004, 64(3): 622-627.

共引文献5348

同被引文献90

引证文献7

二级引证文献231

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部